Polyautoimmunity in Patients With Anticyclic Citrullinated Peptide Antibody–Positive and –Negative Rheumatoid Arthritis: a Nationwide Cohort Study From Denmark
Main finding · Prevalence of prespecified polyautoimmune diseases at first visitResult — go to the resultPrevalence ratio 0.93 95% CI 0.84–1.05Authors' conclusion
Polyautoimmunity as captured through the Danish National Patient Registry occurred in approximately 1 in 10 patients with RA at time of diagnosis regardless of anti-CCP status. In the years subsequent to the RA diagnosis, only a few and mainly anti-CCP-negative patients developed autoimmune disease.
Study context
- Population
- Patients with rheumatoid arthritis (RA) (disease duration ≤ 2 yrs) in the DANBIO register with an available anti-CCP test, Denmark
- Participants
- 5,839 vs 3,799
- Exposure
- Anti-CCP-positive vs anti-CCP-negative RA
- Anti-CCP-positiven = 5,839
- Anti-CCP-negativen = 3,799reference
- Outcome
- Prevalence and incidence of polyautoimmunity (21 nonrheumatic autoimmune diseases)
Methodological detailsnationwide, register-based, age- and sex-adjusted modified Poisson regression, cause-specific Cox regression
- Nationwide
- Register-based
- Age- and sex-adjusted modified Poisson regression
- Cause-specific Cox regression
Main finding
As reported in the abstract
Prevalence of prespecified polyautoimmune diseases at first visit
Prevalence ratio
0.93
95% CI 0.84–1.05
By group
Anti-CCP-positivevs Anti-CCP-negative
PR 0.93 (95% CI 0.84–1.05)
Observational data: associations, not effects.
Further findings
Incident polyautoimmunity within 5 years of entry into DANBIO · mean follow-up of 3.5 years
- Patients who developed polyautoimmunity
- 210
- HR of polyautoimmunity, cause-specific Cox regression
- 0.6 (95% CI 0.46-0.79)
- Only a few and mainly anti-CCP-negative patients developed autoimmune disease
Original publication
Polyautoimmunity in Patients With Anticyclic Citrullinated Peptide Antibody–Positive and –Negative Rheumatoid Arthritis: a Nationwide Cohort Study From Denmark. J Rheumatol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →